Medicine and Dentistry
Asthma
94%
Uveitis
82%
Cytomegalovirus Retinitis
69%
Visual Acuity
54%
Steroid Treatment
49%
Placebo
33%
Systemic Therapy
31%
Fluocinolone Acetonide
30%
Chronic Obstructive Pulmonary Disease
27%
Macular Edema
26%
Highly Active Antiretroviral Therapy
26%
Quality of Life
25%
Disease
23%
Randomized Clinical Trial
23%
Symptom
22%
Clinical Trial
20%
Implant
19%
Retinitis
18%
Visual Impairment
18%
Adolescent
15%
Dexamethasone
14%
Cohort Analysis
14%
Clinical Research
13%
Best Corrected Visual Acuity
13%
Emphysema
12%
Losartan
12%
Visual Field
12%
Airway Obstruction
12%
Granulomatosis with Polyangiitis
12%
Immune Reconstitution
12%
Patient with Asthma
11%
Glaucoma
11%
Cataract Surgery
11%
Electronic Cigarette
10%
Acquired Immune Deficiency Syndrome
10%
Intraocular Pressure
10%
Lansoprazole
10%
Public Health
10%
Sex Difference
9%
Influenza Vaccine
9%
National Eye Institute Visual Function Questionnaire
9%
Human Immunodeficiency Virus
9%
Beta Adrenergic Receptor Stimulating Agent
9%
Anti-Inflammatory Drug
9%
Mental Health
9%
COVID-19
9%
Optical Coherence Tomography
9%
Methotrexate
8%
Body Mass Index
8%
Continuous Positive Airway Pressure
7%
Keyphrases
Asthma
65%
Uveitis
49%
Cytomegalovirus Retinitis
37%
Treatment Trials
35%
Asthma Control
32%
Steroid Treatment
31%
Poorly Controlled Asthma
30%
Clinical Trials
27%
Confidence Interval
27%
Obesity
26%
Panuveitis
26%
Placebo
26%
Randomized Clinical Trial
24%
Visual Acuity
23%
Systemic Therapy
21%
Uveitic Macular Edema
21%
Macular Edema
21%
Risk Factors
21%
Asthma Symptoms
19%
Chronic Obstructive Pulmonary Disease
19%
Asthma Exacerbation
17%
Forced Expiratory Volume in 1 Second (FEV1)
17%
Fluocinolone Acetonide Implant
17%
Montelukast
17%
Emphysema Progression
16%
Losartan
16%
Step-down
15%
Highly Active Antiretroviral Therapy (HAART)
13%
Relative Risk
12%
Cataract Surgery
12%
Inhaled Corticosteroids
12%
Hazard Ratio
12%
Multicenter Clinical Trial
11%
Best-corrected Visual Acuity
11%
Asthmatic
11%
Randomized Trial
11%
Inactivated Influenza Vaccine
10%
People with Obesity
10%
Asthma Outcomes
10%
Implant Therapy
10%
Filgrastim
9%
Former Smokers
9%
Self-selected Diet
9%
VFQ-25
9%
Systemic Anti-inflammatory Therapy
9%
Ganciclovir
9%
AIDS-related
9%
Long-acting beta-agonists
9%
Foscarnet
9%
Older Adults
9%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Uveitis
48%
Disease
34%
Placebo
30%
Randomized Clinical Trial
25%
Chronic Obstructive Lung Disease
25%
Symptom
20%
Steroid Treatment
20%
Clinical Trial
20%
Cytomegalovirus Retinitis
19%
Macular Edema
18%
Lansoprazole
14%
Wegener Granulomatosis
14%
Fructose
14%
Dexamethasone
14%
Emphysema
12%
Losartan
12%
Implant
12%
Glaucoma
11%
Influenza Vaccine
10%
Etanercept
9%
CYP2C19
9%
Beta Adrenergic Receptor Stimulating Agent
9%
Anti-Inflammatory Drug
9%
Inflammation
9%
Fluocinolone Acetonide
9%
Methotrexate
8%
Cohort Study
8%
Montelukast
8%
Fluticasone
8%
Infection
7%
Copper Deficiency
7%
Ranibizumab
7%
Randomized Controlled Trial
7%
Adverse Event
7%
Cataract
6%
Clinical Research
6%
Methacholine
6%
Generalized Anxiety Disorder
5%
Coronavirinae
5%
Respiratory Tract Inflammation
5%
Sinusitis
5%
Respiratory Tract Infection
5%
Visual Impairment
5%
Biological Marker
5%
Respiratory Tract Disease
5%
Corticosteroid
5%
Coughing
5%
